A Breakthrough 50 Years in the Making: FDA Approves First Drug to Directly Target Pancreatic Cancer’s Primary Driver

RASONQUE Represents a Watershed Moment for a Disease That Has Resisted Treatment Since RAS Was Discovered as a Cancer-Causing Gene Pancreatic cancer is among the cruelest malignancies. It develops silently,…

Continue Reading A Breakthrough 50 Years in the Making: FDA Approves First Drug to Directly Target Pancreatic Cancer’s Primary Driver

New Consensus Recommendations Aim to Strengthen Communication and Decision-Making in Neuroblastoma Care

As reported on GlobeNewswire, a newly published set of expert consensus recommendations is seeking to improve the care experience for children diagnosed with neuroblastoma and the families who support them.…

Continue Reading New Consensus Recommendations Aim to Strengthen Communication and Decision-Making in Neuroblastoma Care

A Simple Blood Test Could Predict Which Myeloma Patients Face Hidden Neurological Danger from CAR-T Therapy

Researchers Discover That One of Medicine's Most Common Lab Tests May Warn of Rare But Serious Side Effects Weeks Before They Occur As reported on Inside Precision Medicine, CAR-T cell…

Continue Reading A Simple Blood Test Could Predict Which Myeloma Patients Face Hidden Neurological Danger from CAR-T Therapy

TransThera Secures China’s First Approval for Patients With FGFR Inhibitor-Resistant Cholangiocarcinoma

As reported by allsci, China’s National Medical Products Administration (NMPA) has granted conditional approval to TransThera Sciences’ Yochanra (tinengotinib) for adults with unresectable, advanced, or metastatic cholangiocarcinoma (CCA) carrying FGFR2…

Continue Reading TransThera Secures China’s First Approval for Patients With FGFR Inhibitor-Resistant Cholangiocarcinoma

“The Aftermath: Nobody Told Me This Part Would Hurt Too: – Megan’s Fight Against Non-Hodgkin’s Lymphoma

Editor's Note: Patient Worthy is proud to share this story from our friends at Elephants & Tea. To see the story in its original format, please click here. “Well, good…

Continue Reading “The Aftermath: Nobody Told Me This Part Would Hurt Too: – Megan’s Fight Against Non-Hodgkin’s Lymphoma

It Was All a Dream

Editor's Note: Patient Worthy is honored to share Michelle Patidar's patient story, provided to us by our friends at Elephants & Tea. To see the article in its original format,…

Continue Reading It Was All a Dream

Incyte Reports Positive Phase III Results for Tafasitamab in First-Line DLBCL Treatment

Incyte has announced encouraging top-line findings from its pivotal Phase III frontMIND trial, evaluating tafasitamab (marketed as Monjuvi/Minjuvi) in combination with lenalidomide and the standard R-CHOP regimen for newly diagnosed…

Continue Reading Incyte Reports Positive Phase III Results for Tafasitamab in First-Line DLBCL Treatment

FDA Approves J&J’s Akeega for BRCA2-Mutated mCSPC, Marking a New Era in Precision Prostate Cancer Care

As reported on FiercePharma, Johnson & Johnson has secured a significant milestone in prostate cancer treatment with the FDA’s approval of Akeega for patients with BRCA2-mutated metastatic castration-sensitive prostate cancer…

Continue Reading FDA Approves J&J’s Akeega for BRCA2-Mutated mCSPC, Marking a New Era in Precision Prostate Cancer Care

Breaking the “Undruggable” Barrier: FOG-001 Earns FDA Fast Track for Rare Soft-Tissue Cancer

Parabilis Medicines has achieved a significant milestone in cancer drug development, receiving FDA Fast Track designation for FOG-001, a groundbreaking first-in-class therapy targeting desmoid tumors. As reported by Drugs.com, this…

Continue Reading Breaking the “Undruggable” Barrier: FOG-001 Earns FDA Fast Track for Rare Soft-Tissue Cancer